ovarian endometrial cancer

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, fallopian tube disorder, fallopian tube endometrioid tumor, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, ovarian endometrial cancer	Active, not recruiting	Phase 2	2026-08-26		NCT04034927

Clinical trials